Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Acquires 5,242 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Thomas Chen purchased 5,242 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of $3.81 per share, with a total value of $19,972.02. Following the completion of the acquisition, the chief executive officer owned 24,503 shares in the company, valued at $93,356.43. This represents a 27.22% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Neonc Technologies Trading Down 12.4%

NASDAQ:NTHI traded down $0.47 during mid-day trading on Tuesday, hitting $3.31. The company had a trading volume of 285,988 shares, compared to its average volume of 104,731. The business has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $5.27. Neonc Technologies Holdings, Inc. has a 1 year low of $3.01 and a 1 year high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last issued its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NTHI. Alliance Global Partners initiated coverage on Neonc Technologies in a report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, September 8th. Maxim Group assumed coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 target price on the stock. Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $16.00.

Key Headlines Impacting Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Institutional Trading of Neonc Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE acquired a new stake in Neonc Technologies in the second quarter valued at $1,017,000. BlackRock Inc. acquired a new position in Neonc Technologies during the 2nd quarter worth $815,000. Westmount Partners LLC increased its position in shares of Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Neonc Technologies in the 2nd quarter valued at about $126,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.